QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)

Tharimmune (THAR) Competitors

$0.40
-0.01 (-2.41%)
(As of 02/28/2024 ET)

THAR vs. OBSV, JAN, ARTL, KPRX, BPTS, GOVX, PTIX, IMNN, XCUR, and SONN

Should you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include ObsEva (OBSV), JanOne (JAN), Artelo Biosciences (ARTL), Kiora Pharmaceuticals (KPRX), Biophytis (BPTS), GeoVax Labs (GOVX), Protagenic Therapeutics (PTIX), Imunon (IMNN), Exicure (XCUR), and Sonnet BioTherapeutics (SONN). These companies are all part of the "pharmaceutical preparations" industry.

Tharimmune vs.

ObsEva (NASDAQ:OBSV) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 13.4% of Tharimmune shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 30.2% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ObsEva received 319 more outperform votes than Tharimmune when rated by MarketBeat users.

CompanyUnderperformOutperform
ObsEvaOutperform Votes
319
54.44%
Underperform Votes
267
45.56%
TharimmuneN/AN/A

ObsEva's return on equity of -217.25% beat Tharimmune's return on equity.

Company Net Margins Return on Equity Return on Assets
ObsEvaN/A -416.36% -92.01%
Tharimmune N/A -217.25%-159.07%

ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.

In the previous week, ObsEva had 1 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for ObsEva and 2 mentions for Tharimmune. ObsEva's average media sentiment score of 0.96 beat Tharimmune's score of 0.00 indicating that Tharimmune is being referred to more favorably in the news media.

Company Overall Sentiment
ObsEva Neutral
Tharimmune Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ObsEva
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Tharimmune
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Tharimmune has lower revenue, but higher earnings than ObsEva. ObsEva is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ObsEva$20.11M0.27-$58.38M-$0.92-0.08
TharimmuneN/AN/A-$9.32M-$16.25-0.02

Summary

ObsEva and Tharimmune tied by winning 6 of the 12 factors compared between the two stocks.


Get Tharimmune News Delivered to You Automatically

Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

THAR vs. The Competition

MetricTharimmunePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.76M$6.63B$4.98B$7.46B
Dividend YieldN/A2.64%2.90%3.88%
P/E Ratio-0.0213.19249.8517.99
Price / SalesN/A174.303,081.9064.73
Price / CashN/A19.8195.4054.69
Price / Book0.524.774.464.66
Net Income-$9.32M$155.65M$113.11M$210.88M
7 Day Performance8.12%6.81%5.07%2.50%
1 Month Performance-13.28%14.28%13.01%4.83%
1 Year PerformanceN/A7.14%12.14%7.55%

Tharimmune Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OBSV
ObsEva
0 of 5 stars
$0.06
-15.4%
N/A-27.4%$4.29M$20.11M-0.0648News Coverage
JAN
JanOne
0 of 5 stars
$0.91
-5.2%
N/A-36.6%$4.51M$39.61M0.00199Short Interest ↑
ARTL
Artelo Biosciences
3.3573 of 5 stars
$1.60
-3.6%
$32.50
+1,931.3%
-46.0%$4.58MN/A-0.485Short Interest ↓
KPRX
Kiora Pharmaceuticals
3.5062 of 5 stars
$0.60
-9.2%
$7.00
+1,075.1%
-85.7%$4.58MN/A0.0012Short Interest ↓
BPTS
Biophytis
3.0192 of 5 stars
$0.49
-3.9%
$15.00
+2,955.0%
-87.5%$4.78MN/A0.0026Short Interest ↓
Gap Down
GOVX
GeoVax Labs
3.0137 of 5 stars
$2.23
-5.5%
$90.00
+3,935.9%
-74.2%$3.97M$80,000.00-0.1714Upcoming Earnings
Short Interest ↑
News Coverage
PTIX
Protagenic Therapeutics
0 of 5 stars
$0.88
-12.0%
N/A+79.8%$3.91MN/A0.00N/AShort Interest ↓
Positive News
High Trading Volume
IMNN
Imunon
1.4715 of 5 stars
$0.54
-5.3%
$12.00
+2,122.2%
-50.0%$5.08M$500,000.00-0.1731Short Interest ↑
News Coverage
XCUR
Exicure
2.1828 of 5 stars
$0.59
flat
N/A-49.2%$5.09M$28.83M0.357Gap Up
SONN
Sonnet BioTherapeutics
0.9161 of 5 stars
$1.67
+1.8%
$88.70
+5,211.4%
-90.0%$5.13M$150,000.000.0012Short Interest ↑
Gap Up

Related Companies and Tools

This page (NASDAQ:THAR) was last updated on 2/28/2024 by MarketBeat.com Staff